{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:56:46Z","timestamp":1786982206095,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,3,21]],"date-time":"2018-03-21T00:00:00Z","timestamp":1521590400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s12032-018-1115-6","type":"journal-article","created":{"date-parts":[[2018,3,21]],"date-time":"2018-03-21T04:16:37Z","timestamp":1521605797000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Gemcitabine\u2013cisplatin (GC) as adjuvant chemotherapy in resected stage II and stage III gallbladder cancers (GBC): a potential way forward"],"prefix":"10.1007","volume":"35","author":[{"given":"Vikas","family":"Ostwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Swami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shraddha","family":"Patkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swaratika","family":"Majumdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaesta","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Engineer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarika","family":"Mandavkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8169-4264","authenticated-orcid":false,"given":"Anant","family":"Ramaswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,21]]},"reference":[{"issue":"7","key":"1115_CR1","doi-asserted-by":"publisher","first-page":"djw324","DOI":"10.1093\/jnci\/djw324","volume":"109","author":"T Mitin","year":"2017","unstructured":"Mitin T, Enestvedt CK, Jemal A, Sineshaw HM. Limited use of adjuvant therapy in patients with resected gallbladder cancer despite a strong association with survival. J Natl Cancer Inst. 2017;109(7):djw324.","journal-title":"J Natl Cancer Inst"},{"issue":"16","key":"1115_CR2","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1200\/JCO.2011.40.5381","volume":"30","author":"AM Horgan","year":"2012","unstructured":"Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30(16):1934\u201340.","journal-title":"J Clin Oncol"},{"key":"1115_CR3","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1186\/s12885-015-1617-y","volume":"15","author":"N Ma","year":"2015","unstructured":"Ma N, Cheng H, Qin B, Zhong R, Wang B. Adjuvant therapy in the treatment of gallbladder cancer: a meta-analysis. BMC Cancer. 2015;15:615.","journal-title":"BMC Cancer"},{"issue":"9","key":"1115_CR4","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.hpb.2017.05.010","volume":"19","author":"M Ghidini","year":"2017","unstructured":"Ghidini M, Tomasello G, Botticelli A, Barni S, Zabbialini G, Seghezzi S, et al. Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis. HPB. 2017;19(9):741\u20138.","journal-title":"HPB"},{"key":"1115_CR5","doi-asserted-by":"crossref","unstructured":"Edeline J, Bonnetain F, Phelip JM, Watelet J, Hammel P, Joly J-P, et al. Gemox versus surveillance following surgery of localized biliary tract cancer: results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial. J Clin Oncol [Internet]. 2017; 35(suppl 4S; abstract 225). http:\/\/meetinglibrary.asco.org\/content\/176861-195 . Cited 22 Mar 2017.","DOI":"10.1200\/JCO.2017.35.4_suppl.225"},{"issue":"15_suppl","key":"1115_CR6","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1200\/JCO.2017.35.15_suppl.4006","volume":"35","author":"JN Primrose","year":"2017","unstructured":"Primrose JN, Fox R, Palmer DH, Prasad R, Mirza D, Anthoney DA, et al. Adjuvant capecitabine for biliary tract cancer: the BILCAP randomized study. J Clin Oncol. 2017;35(15_suppl):4006.","journal-title":"J Clin Oncol"},{"issue":"14","key":"1115_CR7","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381.","journal-title":"N Engl J Med"},{"issue":"5","key":"1115_CR8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.6004\/jnccn.2017.0059","volume":"15","author":"AB Benson","year":"2017","unstructured":"Benson AB, D\u2019Angelica MI, Abbott DE, Abrams TA, Alberts SR, Saenz DA, et al. NCCN guidelines insights: hepatobiliary cancers, Version 1.2017. J Natl Compr Cancer Netw. 2017;15(5):563\u201373.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"11","key":"1115_CR9","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/jhbp.283","volume":"22","author":"O Kainuma","year":"2015","unstructured":"Kainuma O, Miura F, Furukawa D, Yamamoto H, Cho A, Sano K, et al. Feasibility and efficacy of gemcitabine plus cisplatin combination therapy after curative resection for biliary tract cancer. J Hepato-Biliary-Pancreat Sci. 2015;22(11):789\u201394.","journal-title":"J Hepato-Biliary-Pancreat Sci"},{"issue":"18","key":"1115_CR10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12885-017-3967-0","volume":"11","author":"AR Siebenh\u00fcner","year":"2018","unstructured":"Siebenh\u00fcner AR, Seifert H, Bachmann H, Seifert B, Winder T, Feilchenfeldt J, et al. Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: a prospective single center phase II study. BMC Cancer. 2018;11(18):72.","journal-title":"BMC Cancer"},{"issue":"3","key":"1115_CR11","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/jso.24837","volume":"117","author":"S Patkar","year":"2018","unstructured":"Patkar S, Ostwal V, Ramaswamy A, Engineer R, Chopra S, Shetty N, et al. Emerging role of multimodality treatment in gall bladder cancer: Outcomes following 510 consecutive resections in a tertiary referral center. J Surg Oncol. 2018;117(3):372\u20139.","journal-title":"J Surg Oncol"},{"key":"1115_CR12","unstructured":"WMA\u2014The World Medical Association. WMA Declaration of Helsinki\u2014Ethical principles for medical research involving human subjects [Internet]. https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects\/ . Cited 25 Jan 2018."},{"issue":"2","key":"1115_CR13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.4103\/0973-1482.25850","volume":"2","author":"UM Mahantshetty","year":"2006","unstructured":"Mahantshetty UM, Palled SR, Engineer R, Homkar G, Shrivastava SK, Shukla PJ. Adjuvant radiation therapy in gall bladder cancers: 10\u00a0years experience at Tata Memorial Hospital. J Cancer Res Ther. 2006;2(2):52\u20136.","journal-title":"J Cancer Res Ther"},{"issue":"21","key":"1115_CR14","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1200\/JCO.2009.27.4787","volume":"28","author":"AF Hezel","year":"2010","unstructured":"Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol. 2010;28(21):3531\u201340.","journal-title":"J Clin Oncol"},{"issue":"17","key":"1115_CR15","doi-asserted-by":"publisher","first-page":"14744","DOI":"10.18632\/oncotarget.4539","volume":"6","author":"G Brandi","year":"2015","unstructured":"Brandi G, Farioli A, Astolfi A, Biasco G, Tavolari S. Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies. Oncotarget. 2015;6(17):14744\u201353.","journal-title":"Oncotarget"},{"issue":"8","key":"1115_CR16","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/ng.3030","volume":"46","author":"M Li","year":"2014","unstructured":"Li M, Zhang Z, Li X, Ye J, Wu X, Tan Z, et al. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. Nat Genet. 2014;46(8):872\u20136.","journal-title":"Nat Genet"},{"issue":"6","key":"1115_CR17","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/sj.bjc.6603648","volume":"96","author":"F Eckel","year":"2007","unstructured":"Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer. 2007;96(6):896\u2013902.","journal-title":"Br J Cancer"},{"issue":"6","key":"1115_CR18","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/sj.bjc.6604628","volume":"99","author":"T Andr\u00e9","year":"2008","unstructured":"Andr\u00e9 T, Reyes-Vidal JM, Fartoux L, Ross P, Leslie M, Rosmorduc O, et al. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer. 2008;99(6):862\u20137.","journal-title":"Br J Cancer"},{"issue":"8","key":"1115_CR19","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1002\/cncr.10831","volume":"95","author":"T Takada","year":"2002","unstructured":"Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002;95(8):1685\u201395.","journal-title":"Cancer"},{"issue":"24","key":"1115_CR20","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1200\/JCO.2014.60.2219","volume":"33","author":"E Ben-Josef","year":"2015","unstructured":"Ben-Josef E, Guthrie KA, El-Khoueiry AB, Corless CL, Zalupski MM, Lowy AM, et al. SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol. 2015;33(24):2617\u201322.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1115_CR21","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","volume":"17","author":"SB Edge","year":"2010","unstructured":"Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471\u20134.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"1115_CR22","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/cncr.11699","volume":"98","author":"WR Jarnagin","year":"2003","unstructured":"Jarnagin WR, Ruo L, Little SA, Klimstra D, D\u2019Angelica M, DeMatteo RP, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer. 2003;98(8):1689\u2013700.","journal-title":"Cancer"},{"issue":"7","key":"1115_CR23","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1111\/hpb.12188","volume":"16","author":"JK Wiggers","year":"2014","unstructured":"Wiggers JK, Groot Koerkamp B, Ovadia Z, Busch ORC, Gouma DJ, van Gulik TM. Patterns of recurrence after resection of gallbladder cancer without routine extrahepatic bile duct resection. HPB. 2014;16(7):635\u201340.","journal-title":"HPB"},{"issue":"15","key":"1115_CR24","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1186\/s12885-015-1498-0","volume":"31","author":"A Stein","year":"2015","unstructured":"Stein A, Arnold D, Bridgewater J, Goldstein D, Jensen LH, Kl\u00fcmpen H-J, et al. Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial)\u2014a randomized, multidisciplinary, multinational phase III trial. BMC Cancer. 2015;31(15):564.","journal-title":"BMC Cancer"},{"issue":"2","key":"1115_CR25","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/j.1477-2574.2009.00149.x","volume":"12","author":"I Hatzaras","year":"2010","unstructured":"Hatzaras I, Schmidt C, Muscarella P, Melvin WS, Ellison EC, Bloomston M. Elevated CA 19-9 portends poor prognosis in patients undergoing resection of biliary malignancies. HPB. 2010;12(2):134\u20138.","journal-title":"HPB."},{"key":"1115_CR26","first-page":"1","volume":"20","author":"S Agrawal","year":"2017","unstructured":"Agrawal S, Lawrence A, Saxena R. Does CA 19-9 have prognostic relevance in gallbladder carcinoma (GBC)? J Gastrointest Cancer. 2017;20:1\u20136.","journal-title":"J Gastrointest Cancer"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-018-1115-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-018-1115-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-018-1115-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,13]],"date-time":"2019-10-13T02:04:59Z","timestamp":1570932299000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-018-1115-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,21]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["1115"],"URL":"https:\/\/doi.org\/10.1007\/s12032-018-1115-6","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,21]]},"assertion":[{"value":"26 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee as well as with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Ethics committee approval number: IEC\/1017\/1880\/001.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable as this is a retrospective study of prospective database with no direct contact with the patients. Institutional Ethics committee approved waiver of consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"57"}}